A new trial involving survodutide was posted on clinicaltrials.gov, dated August 18, 2026. The study, registered as NCT07768813, is titled "A Study to Compare How 2 Different Formulations of Survodutide Are Taken up in the Body When Given by Injection in Healthy Men and Women With and Without Overweight or Obesity."
The trial is listed as Phase 1 and its current status is not yet recruiting. According to the registration, the study is designed to compare how two different formulations of survodutide behave in the body after injection. It will include healthy men and women, as well as participants with and without overweight or obesity.
No results, efficacy data, or safety findings have been posted for this trial at this time. Survodutide remains an unapproved compound under research and is not authorized for clinical use outside of trial settings. As with any early-phase study, timelines and participant enrollment may change before recruitment begins.
Readers interested in background on this compound can consult the survodutide overview page for additional context.